Susan E. Hankinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan E. Hankinson has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- A. Heather Eliassen
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
25 shared publications - Allison F. Vitonis
Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
12 shared publications - Amy L. Shafrir
Division of Adolescent/Young Adult Medicine, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
12 shared publications - Daniel William Cramer
Brigham and Women's Hospital, Boston, MA
12 shared publications - Robert L. Barbieri
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
12 shared publications - Tianyi Huang
Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging , Baltimore, MD
12 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women
Supplementary Data from A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women
Supplementary Data from A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women
Background:Identifying risk factors for aggressive forms of breast cancer is important. Tumor factors (e.g., stage) are important predictors of prognosis, but may be intermediates between prediagnosis risk factors and mortality. Typically, separate models are fit for incidence and mortality postdiagnosis. These models have not been previously integrated to identify risk factors for lethal breast cancer in cancer-free women.Methods:We combined models for breast cancer incidence and breast cancer–specific mortality among cases into a multi-state survival model for lethal breast cancer. We derived the model from cancer-free postmenopausal Nurses’ Health Study women in 1990 using baseline risk factors. A total of 4,391 invasive breast cancer cases were diagnosed from 1990 to 2014 of which 549 died because of breast cancer over the same period.Results:Some established risk factors (e.g., family history, estrogen plus progestin therapy) were not associated with lethal breast cancer. Controlling for age, the strongest risk factors for lethal breast cancer were weight gain since age 18: > 30 kg versus ± 5 kg, RR = 1.94 [95% confidence interval (CI) = 1.38–2.74], nulliparity versus age at first birth (AAFB) < 25, RR = 1.60 (95% CI = 1.16–2.22), and current smoking ≥ 15 cigarettes/day versus never, RR = 1.42 (95% CI = 1.07–1.89).Conclusions:Some breast cancer incidence risk factors are not associated with lethal breast cancer; other risk factors for lethal breast cancer are not associated with disease incidence.Impact:This multi-state survival model may be useful for identifying prediagnosis factors that lead to more aggressive and ultimately lethal breast cancer.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women
Background:Identifying risk factors for aggressive forms of breast cancer is important. Tumor factors (e.g., stage) are important predictors of prognosis, but may be intermediates between prediagnosis risk factors and mortality. Typically, separate models are fit for incidence and mortality postdiagnosis. These models have not been previously integrated to identify risk factors for lethal breast cancer in cancer-free women.Methods:We combined models for breast cancer incidence and breast cancer–specific mortality among cases into a multi-state survival model for lethal breast cancer. We derived the model from cancer-free postmenopausal Nurses’ Health Study women in 1990 using baseline risk factors. A total of 4,391 invasive breast cancer cases were diagnosed from 1990 to 2014 of which 549 died because of breast cancer over the same period.Results:Some established risk factors (e.g., family history, estrogen plus progestin therapy) were not associated with lethal breast cancer. Controlling for age, the strongest risk factors for lethal breast cancer were weight gain since age 18: > 30 kg versus ± 5 kg, RR = 1.94 [95% confidence interval (CI) = 1.38–2.74], nulliparity versus age at first birth (AAFB) < 25, RR = 1.60 (95% CI = 1.16–2.22), and current smoking ≥ 15 cigarettes/day versus never, RR = 1.42 (95% CI = 1.07–1.89).Conclusions:Some breast cancer incidence risk factors are not associated with lethal breast cancer; other risk factors for lethal breast cancer are not associated with disease incidence.Impact:This multi-state survival model may be useful for identifying prediagnosis factors that lead to more aggressive and ultimately lethal breast cancer.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Supplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Supplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Background:The relationships between PTEN loss and/or PIK3CA mutation and breast cancer prognosis remain controversial. We aim to examine the associations in large epidemiologic cohorts.Methods:We followed women with invasive breast cancer from the Nurses’ Health Studies with available data on tumor PTEN expression (n = 4,111) and PIK3CA mutation (n = 2,930). PTEN expression was evaluated by IHC and digitally scored (0%–100%). Pyrosequencing of six hotspot mutations of PIK3CA was performed.Results:We found loss of PTEN expression (≤10%) occurred in 17% of cases, and PIK3CA mutations were detected in 11% of cases. After adjusting for clinical and lifestyle factors, PTEN loss was not associated with worse breast cancer-specific mortality among all samples [HR, 0.85; 95% confidence intervals (CI), 0.71–1.03] or among estrogen receptor (ER)-positive tumors (HR, 0.99; 95% CI, 0.79–1.24). However, among ER-negative tumors, PTEN loss was associated with lower breast cancer-specific mortality (HR, 0.68; 95% CI, 0.48–0.95). PIK3CA mutation was not strongly associated with breast cancer-specific mortality (HR, 0.89; 95% CI, 0.67–1.17). Compared with tumors without PTEN loss and without PIK3CA mutation, those with alterations (n = 540) were not at higher risk (HR, 1.07; 95% CI, 0.86–1.34). However, women with both PTEN loss and PIK3CA mutation (n = 38) were at an increased risk of breast cancer-specific mortality (HR, 1.65; 95% CI, 0.83–3.26).Conclusions:In this large epidemiologic study, the PTEN-mortality association was more pronounced for ER-negative tumors, and the joint PTEN loss and PIK3CA mutation may be associated with worse prognosis.Impact:Further studies with a larger sample of ER-negative tumors are needed to replicate our findings and elucidate underlying mechanisms.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Background:The relationships between PTEN loss and/or PIK3CA mutation and breast cancer prognosis remain controversial. We aim to examine the associations in large epidemiologic cohorts.Methods:We followed women with invasive breast cancer from the Nurses’ Health Studies with available data on tumor PTEN expression (n = 4,111) and PIK3CA mutation (n = 2,930). PTEN expression was evaluated by IHC and digitally scored (0%–100%). Pyrosequencing of six hotspot mutations of PIK3CA was performed.Results:We found loss of PTEN expression (≤10%) occurred in 17% of cases, and PIK3CA mutations were detected in 11% of cases. After adjusting for clinical and lifestyle factors, PTEN loss was not associated with worse breast cancer-specific mortality among all samples [HR, 0.85; 95% confidence intervals (CI), 0.71–1.03] or among estrogen receptor (ER)-positive tumors (HR, 0.99; 95% CI, 0.79–1.24). However, among ER-negative tumors, PTEN loss was associated with lower breast cancer-specific mortality (HR, 0.68; 95% CI, 0.48–0.95). PIK3CA mutation was not strongly associated with breast cancer-specific mortality (HR, 0.89; 95% CI, 0.67–1.17). Compared with tumors without PTEN loss and without PIK3CA mutation, those with alterations (n = 540) were not at higher risk (HR, 1.07; 95% CI, 0.86–1.34). However, women with both PTEN loss and PIK3CA mutation (n = 38) were at an increased risk of breast cancer-specific mortality (HR, 1.65; 95% CI, 0.83–3.26).Conclusions:In this large epidemiologic study, the PTEN-mortality association was more pronounced for ER-negative tumors, and the joint PTEN loss and PIK3CA mutation may be associated with worse prognosis.Impact:Further studies with a larger sample of ER-negative tumors are needed to replicate our findings and elucidate underlying mechanisms.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Supplemental Table 1: Adjusted geometric mean hormone levels by lifetime ovulatory years quartile among postmenopausal women not using hormone therapy at the time of blood draw in the Nurses' Health Study; excluding hysterectomized women whose age at menopause was n=1683
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Background:Lifetime ovulatory years (LOY) is estimated by the difference between ages at menopause and menarche subtracting time for events interrupting ovulation. We tested whether LOY influences sex hormone levels in postmenopausal women with at least one intact ovary not using hormones.Methods:Estradiol, estrone, estrone sulfate, total testosterone, dehydroepiandrostendione sulfate, prolactin, and sex hormone binding globulin were measured in 1,976 postmenopausal women from the Nurses’ Health Study. Associations of age, body mass index (BMI), smoking, alcohol use, and other factors on hormones were assessed by t tests and ANOVA. Linear regression was used to assess multivariable adjusted associations between LOY and hormones and trends in hormone levels per 5-year increases in LOY were estimated.Results:Women averaged 61.4 years old, 11.0 years since menopause, with BMI of 25.8 kg/m2. A total of 13.6% had irregular cycles, 17.5% hysterectomy, 6.4% unilateral oophorectomy, and 13.8% were current smokers. Variables associated with one or more hormone levels were included as covariates. Each 5-year increase in LOY was significantly associated with a 5.2% increase in testosterone in women with BMI < 25 kg/m2 and a 7.4% increase in testosterone and 7.3% increase in estradiol in women with above-average BMI.Conclusions:This is the first study to show that greater LOY is associated with higher testosterone in postmenopausal women and higher estradiol in those with elevated BMI, suggesting accumulation of functioning stromal and thecal cells from repeated ovulations and peripheral conversion of testosterone.Impact:A possible explanation for why greater LOY increases risk for breast, endometrial, and ovarian cancer is offered.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Estimated Ovulatory Years Prior to Menopause and Postmenopausal Endogenous Hormone Levels
Background:Lifetime ovulatory years (LOY) is estimated by the difference between ages at menopause and menarche subtracting time for events interrupting ovulation. We tested whether LOY influences sex hormone levels in postmenopausal women with at least one intact ovary not using hormones.Methods:Estradiol, estrone, estrone sulfate, total testosterone, dehydroepiandrostendione sulfate, prolactin, and sex hormone binding globulin were measured in 1,976 postmenopausal women from the Nurses’ Health Study. Associations of age, body mass index (BMI), smoking, alcohol use, and other factors on hormones were assessed by t tests and ANOVA. Linear regression was used to assess multivariable adjusted associations between LOY and hormones and trends in hormone levels per 5-year increases in LOY were estimated.Results:Women averaged 61.4 years old, 11.0 years since menopause, with BMI of 25.8 kg/m2. A total of 13.6% had irregular cycles, 17.5% hysterectomy, 6.4% unilateral oophorectomy, and 13.8% were current smokers. Variables associated with one or more hormone levels were included as covariates. Each 5-year increase in LOY was significantly associated with a 5.2% increase in testosterone in women with BMI < 25 kg/m2 and a 7.4% increase in testosterone and 7.3% increase in estradiol in women with above-average BMI.Conclusions:This is the first study to show that greater LOY is associated with higher testosterone in postmenopausal women and higher estradiol in those with elevated BMI, suggesting accumulation of functioning stromal and thecal cells from repeated ovulations and peripheral conversion of testosterone.Impact:A possible explanation for why greater LOY increases risk for breast, endometrial, and ovarian cancer is offered.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Data from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
Background:Estradiol and estrone are well-established risk factors for postmenopausal breast cancer. Experimental evidence suggests that specific estrogen metabolites, produced via irreversible hydroxylation of estrone and estradiol at position 2 or 16, may independently influence carcinogenesis.Methods:We performed a nested case–control study of breast cancer (328 breast cancer cases; 639 controls) among postmenopausal women within the Nurses’ Health Study to examine the role of estrogens and estrogen metabolites (jointly referred to as EM). Plasma concentrations of each EM (unconjugated + conjugated forms) were measured by LC-MS/MS. Multivariable conditional logistic regression, adjusting for breast cancer risk factors, estimated relative risks (RR) and 95% confidence intervals of breast cancer across quintiles of individual EM, EM pathways, and pathway ratios. Associations by estrogen receptor (ER) and progesterone receptor (PR) status were analyzed by unconditional logistic regression.Results:Estradiol and estrone were strongly associated with increased breast cancer risk [estradiol: RRQ5 vs. Q1 (95% confidence interval) = 2.64 (1.64–4.26); estrone: 2.78 (1.74–4.45); both P-trends <0.001]. The 2-hydroxylation pathway was strongly associated with risk [RRQ5 vs. Q1 = 3.09 (1.81–5.27); P-trend <0.001] and remained so after adjusting for unconjugated estradiol [RRQ5 vs. Q1 = 2.23 (1.25–3.96); P-trend = 0.01]. Although the 16-hydroxylation pathway was modestly associated with risk [RRQ5 vs. Q1 = 1.62 (1.03–2.54); P-trend = 0.01], the association was attenuated after unconjugated estradiol adjustment [RRQ5 vs. Q1 = 1.24 (0.77–1.99); P-trend = 0.19]. Similar positive associations with the 2-pathway and 16-pathway were observed for ER+/PR+ and ER−/PR− tumors.Conclusions:In this cohort of postmenopausal women, 2-hydroxylation of estrone and estradiol was associated with increased breast cancer risk, independent of unconjugated estradiol.Impact:These results highlight the need to revisit the role of estrogen metabolism in breast cancer etiology and prevention.See related In the Spotlight, p. 367
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
Background:Estradiol and estrone are well-established risk factors for postmenopausal breast cancer. Experimental evidence suggests that specific estrogen metabolites, produced via irreversible hydroxylation of estrone and estradiol at position 2 or 16, may independently influence carcinogenesis.Methods:We performed a nested case–control study of breast cancer (328 breast cancer cases; 639 controls) among postmenopausal women within the Nurses’ Health Study to examine the role of estrogens and estrogen metabolites (jointly referred to as EM). Plasma concentrations of each EM (unconjugated + conjugated forms) were measured by LC-MS/MS. Multivariable conditional logistic regression, adjusting for breast cancer risk factors, estimated relative risks (RR) and 95% confidence intervals of breast cancer across quintiles of individual EM, EM pathways, and pathway ratios. Associations by estrogen receptor (ER) and progesterone receptor (PR) status were analyzed by unconditional logistic regression.Results:Estradiol and estrone were strongly associated with increased breast cancer risk [estradiol: RRQ5 vs. Q1 (95% confidence interval) = 2.64 (1.64–4.26); estrone: 2.78 (1.74–4.45); both P-trends <0.001]. The 2-hydroxylation pathway was strongly associated with risk [RRQ5 vs. Q1 = 3.09 (1.81–5.27); P-trend <0.001] and remained so after adjusting for unconjugated estradiol [RRQ5 vs. Q1 = 2.23 (1.25–3.96); P-trend = 0.01]. Although the 16-hydroxylation pathway was modestly associated with risk [RRQ5 vs. Q1 = 1.62 (1.03–2.54); P-trend = 0.01], the association was attenuated after unconjugated estradiol adjustment [RRQ5 vs. Q1 = 1.24 (0.77–1.99); P-trend = 0.19]. Similar positive associations with the 2-pathway and 16-pathway were observed for ER+/PR+ and ER−/PR− tumors.Conclusions:In this cohort of postmenopausal women, 2-hydroxylation of estrone and estradiol was associated with increased breast cancer risk, independent of unconjugated estradiol.Impact:These results highlight the need to revisit the role of estrogen metabolism in breast cancer etiology and prevention.See related In the Spotlight, p. 367
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
TS2 provides the concentrations in pmol/L for each EM or EM pathway in our cohort (NHS) compared to PLCO.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
TS2 provides the concentrations in pmol/L for each EM or EM pathway in our cohort (NHS) compared to PLCO.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
Supplementary Table 3 shows the Spearman correlations among individual estrogens/estrogen metabolites (EM)
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
Supplementary Table 3 shows the Spearman correlations among individual estrogens/estrogen metabolites (EM)
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
Table S1 provides details on coefficents of variation (CVs) and limits of detection (LOD) for individual estrogens/estrogen metabolites.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses’ Health Study
Table S1 provides details on coefficents of variation (CVs) and limits of detection (LOD) for individual estrogens/estrogen metabolites.